Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cyclezyme ABXSAT:CYCLE -2.05%8 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates XSAT:CYCLE with a GF Score™ of 8/100. The stock has 3 warning signs investors should review. Among 1,577 Chemicals companies, Cyclezyme AB ranks worse than 98.22% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cyclezyme AB's EBITDA for the
three
months ended in Mar. 2026 was kr-0.81 Mil. Cyclezyme AB's Revenue for the
three
months ended in Mar. 2026 was kr0.00 Mil. Therefore, Cyclezyme AB's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
Cyclezyme AB (XSAT:CYCLE) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cyclezyme AB EBITDA Margin % Related Terms
Cyclezyme AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cyclezyme AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:CYCLE vs LIN, SHW, ECL: EBITDA Margin % Comparison
For the Specialty Chemicals subindustry, Cyclezyme AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclezyme AB EBITDA Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Cyclezyme AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cyclezyme AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclezyme AB (XSAT:CYCLE) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cyclezyme AB and its competitors. According to the industry distribution chart, Cyclezyme AB ranks #1549 out of 1577 companies in the Chemicals industry, placing it in the top 98.2%.
Is Cyclezyme AB's EBITDA Margin % too high?
Cyclezyme AB's current EBITDA Margin % is 0.00%. Based on the distribution chart, Cyclezyme AB ranks #1549 out of 1577 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Cyclezyme AB has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Cyclezyme AB's EBITDA Margin % compare to LIN and SHW?
According to the Chemicals industry distribution chart, Cyclezyme AB ranks #1549 out of 1577 companies for EBITDA Margin %. This places Cyclezyme AB in the lower half of its industry. The industry median EBITDA Margin % is 9.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Chemicals company?
The median EBITDA Margin % among Chemicals companies is 9.63, based on 1,577 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cyclezyme AB and its competitors. For the Chemicals industry, the median EBITDA Margin % is 9.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyclezyme AB's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclezyme AB stock overvalued right now?
Cyclezyme AB (XSAT:CYCLE) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Cyclezyme AB's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cyclezyme AB (XSAT:CYCLE), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cyclezyme AB is a Sweden-based company that has developed an enzymatic platform focused on producing enzymes for green biochemical processes. This platform utilizes biotechnological methods to identify and improve enzymes capable of converting e.g. PET-based plastic materials for new building blocks. The company enables careful experiments and analyses of the behavior of different enzymes in the breakdown of e.g. PET material. The company refines its enzymes and also optimizes the processes for plastic recycling by combining experimental data with data analysis.
8GF Score
Get the complete analysis for XSAT:CYCLE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:CYCLE has been successfully added to your 
